Memorial Sloan Kettering Cancer Center (MSK) is driving dramatic progress in the way the world treats cancer. Last week, MSK doctors and scientists presented a wealth of high-impact research at the annual meeting of the American Society of Clinical Oncology, including two practice-changing studies

A multicenter clinical trial led by MSK has discovered the first novel treatment option for low-grade glioma in more than 20 years. Gliomas are the most common type of primary brain cancer in adults, and people with these tumors have few effective long-term treatment options. The study found that the oral drug vorasidenib significantly slowed the growth of certain kinds of early-stage glioma and reduced the need for more toxic therapies, bringing new hope to patients with these cancers. Foundational research for this study was supported by the MSK donor community, including Anthony and Judith Evnin, Cycle for Survival, the William Randolph Hearst Foundation, and the National Brain Tumor Society.